Pediatrix Posts Q3 EPS of 59 Cents
MD sits 69% above its 52-week low of $16.9.
Summary
Pediatrix reported third-quarter EPS of 59 cents, while adjusted EPS came in at 72 cents and net income was $47 million. It is the company's first quarterly print since Q2 adjusted EPS of 63 cents beat estimates and management reaffirmed full-year Adjusted EBITDA guidance of $280–$300 million. The sequential step down from 63 cents to 59 cents is modest, and the headline carries no revenue or guidance update, so the key question is whether the company held that EBITDA range. Shares sit near the 52-week high of $30.045, leaving little room for a soft print. Watch for any guidance revision, plus the Q3 filing for buyback activity under the existing $250 million repurchase program.
At the time of this announcement, MD was trading at $28.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $16.90 to $30.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.